^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EU101

    i
    Other names: EU101, EU-101, NOV1801, HOT-1030
    Associations

    News

    Trials
    Company:
    Eutilex, National OncoVenture, Zhejiang Huahai Pharma
    Drug class:
    CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Eutilex | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Sep 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    MSI-H/dMMR • RAS mutation
    |
    EU101
    over3years
    A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Eutilex | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    MSI-H/dMMR
    |
    EU101
    over3years
    A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=96, Not yet recruiting, Eutilex
    Clinical • New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    MSI-H/dMMR
    |
    EU101